NCT02447939View on ClinicalTrials.gov

Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2017

Primary Completion Date

October 31, 2018

Study Completion Date

December 31, 2018

Conditions
Melanoma
Interventions
DRUG

Dabrafenib

Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt).

DRUG

Trametinib

Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02447939 - Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma | Biotech Hunter | Biotech Hunter